Lung cancer patients with mutations in specific driver genes—such as epidermal growth factor receptor (EGFR), Kirsten rat sarcoma viral oncogene homolog (KRAS), or tumor protein p53 (TP53)—are potential candidates for molecular targeted therapies using matched tyrosine kinase inhibitors [92]. Here, KRAS is linked to lung carcinoma.